Limaprost Description

Limaprost is an articulate prostaglandin E1 analog. Prostaglandins act on a array of beef such as vascular bland beef beef causing binding or dilation, on platelets causing accession or disaggregation and on analgesic neurons causing pain. Prostaglandins accept a advanced array of actions, including, but not bound to able-bodied binding and arbitration of inflammation.

Limaprost alfadex has been apparent to advance borderline circulatory abortion with a vasodilator activity and an antithrombotic effect. It aswell improves poor claret breeze in the assumption tissue in cervical spondylosis and normalizes assumption function. Limaprost alfadex was apparent from collaborative analysis amid Ono Pharmaceutical (Ono) and Dainippon Sumitomo Pharma (DSP). It was accustomed for the analysis of ischemic affection such as derma ulcer, affliction and aloofness accompanying thromboangiitis obliterans in 1988; and for the analysis of abstract affection such as affliction and asleep in the lower leg and walking affliction associated with acquired lumbar analgesic aqueduct binding as an added adumbration in 2001.

The biologic has been awash beneath the barter name of Opalmon® Tablets by Ono and Prorenal® Tablets by DSP. In 2011, Ono and DSP accomplished Phase II analytic trials in Japan for the analysis of carpal adit syndrome. In 2013, these trials were discontinued because the abstraction bootless to authenticate efficacy. Ono and DSP aswell discontinued the development of limaprost alfadex for the added adumbration of cervical spondylosis in 2008 due to the abortion to authenticate the advancing ability in a Phase II abstraction in patients with the disease.

However, it was absolute by Seoul National University Hospital in November of 2014 that the abstraction on the ability of articulate limaprost alfadex afterwards anaplasty for cervical myelopathy was still ongoing.

more about:

Pharmaceutical Ingredients